Bruce H. Morimoto

2.0k total citations
44 papers, 1.2k citations indexed

About

Bruce H. Morimoto is a scholar working on Molecular Biology, Physiology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Bruce H. Morimoto has authored 44 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 13 papers in Physiology and 9 papers in Cellular and Molecular Neuroscience. Recurrent topics in Bruce H. Morimoto's work include Alzheimer's disease research and treatments (10 papers), Cholinesterase and Neurodegenerative Diseases (7 papers) and Neuroscience and Neuropharmacology Research (6 papers). Bruce H. Morimoto is often cited by papers focused on Alzheimer's disease research and treatments (10 papers), Cholinesterase and Neurodegenerative Diseases (7 papers) and Neuroscience and Neuropharmacology Research (6 papers). Bruce H. Morimoto collaborates with scholars based in United States, Israel and United Kingdom. Bruce H. Morimoto's co-authors include D E Koshland, Daniel E. Koshland, Anthony W. Fox, Illana Gozes, Alistair Stewart, Michael R. Nichols, Michael Gold, Julian R. Keith, Joe Hirman and Andrew D. Blackwell and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Neuron.

In The Last Decade

Bruce H. Morimoto

44 papers receiving 1.2k citations

Peers

Bruce H. Morimoto
Laurent Lecanu United States
Marta Tajes Spain
Xénia Latypova France
Jan Říčný Czechia
Jian‐Sheng Kang China
Joo‐Yong Lee South Korea
Shane E. Kruse United States
Zhongmin Xiang United States
Priyanka Narayan United States
Simona Magi Italy
Laurent Lecanu United States
Bruce H. Morimoto
Citations per year, relative to Bruce H. Morimoto Bruce H. Morimoto (= 1×) peers Laurent Lecanu

Countries citing papers authored by Bruce H. Morimoto

Since Specialization
Citations

This map shows the geographic impact of Bruce H. Morimoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bruce H. Morimoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bruce H. Morimoto more than expected).

Fields of papers citing papers by Bruce H. Morimoto

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bruce H. Morimoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bruce H. Morimoto. The network helps show where Bruce H. Morimoto may publish in the future.

Co-authorship network of co-authors of Bruce H. Morimoto

This figure shows the co-authorship network connecting the top 25 collaborators of Bruce H. Morimoto. A scholar is included among the top collaborators of Bruce H. Morimoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bruce H. Morimoto. Bruce H. Morimoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Friedrichs, Gregory S., D.E. Ackley, Matthew Clark, et al.. (2024). Reevaluating safety pharmacology respiratory studies within the ICH S7A core battery: A multi-company evaluation of preclinical utility and clinical translation. Regulatory Toxicology and Pharmacology. 153. 105706–105706. 3 indexed citations
2.
Li, Zhuoxuan, Samuel T. Henderson, Bruce H. Morimoto, et al.. (2022). Modeling digestion, absorption, and ketogenesis after administration of tricaprilin formulations to humans. European Journal of Pharmaceutics and Biopharmaceutics. 182. 41–52. 12 indexed citations
3.
Paglialunga, Sabina, Bruce H. Morimoto, Matthew Clark, & Gregory S. Friedrichs. (2019). Translatability of the S7A core battery respiratory safety pharmacology studies: Preclinical respiratory and related clinical adverse events. Journal of Pharmacological and Toxicological Methods. 99. 106596–106596. 9 indexed citations
4.
Dewji, Nazneen N., Marc R. Azar, Leah R. Hanson, et al.. (2018). Pharmacokinetics in Rat of P8, a Peptide Drug Candidate for the Treatment of Alzheimer’s Disease: Stability and Delivery to the Brain. Journal of Alzheimer s Disease Reports. 2(1). 169–179. 5 indexed citations
5.
Paglialunga, Sabina, et al.. (2018). Evaluating cardiac risk: exposure response analysis in early clinical drug development. Drug Healthcare and Patient Safety. Volume 10. 27–36. 11 indexed citations
6.
Morimoto, Bruce H.. (2017). Therapeutic peptides for CNS indications: Progress and challenges. Bioorganic & Medicinal Chemistry. 26(10). 2859–2862. 21 indexed citations
7.
Bang, Jee, Iryna Lobach, Anthony E. Lang, et al.. (2016). Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials. Parkinsonism & Related Disorders. 28. 41–48. 23 indexed citations
8.
Paglialunga, Sabina, et al.. (2016). Update and trends on pharmacokinetic studies in patients with impaired renal function: practical insight into application of the FDA and EMA guidelines. Expert Review of Clinical Pharmacology. 10(3). 1–11. 22 indexed citations
9.
Morimoto, Bruce H., Erin Castelloe, & Anthony W. Fox. (2015). Safety Pharmacology in Drug Discovery and Development. Handbook of experimental pharmacology. 229. 65–80. 13 indexed citations
10.
11.
Morimoto, Bruce H., Anthony W. Fox, Alistair Stewart, & Michael Gold. (2013). Davunetide: a review of safety and efficacy data with a focus on neurodegenerative diseases. Expert Review of Clinical Pharmacology. 6(5). 483–502. 22 indexed citations
12.
13.
Fleming, Sheila M., Caitlin Mulligan, Franziska Richter, et al.. (2010). A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions. Molecular and Cellular Neuroscience. 46(3). 597–606. 62 indexed citations
14.
Gozes, Illana, et al.. (2009). Addressing Alzheimers Disease Tangles: From NAP to AL-108. Current Alzheimer Research. 6(5). 455–460. 74 indexed citations
15.
Stewart, Alistair, Anthony W. Fox, Bruce H. Morimoto, & Illana Gozes. (2007). Looking for novel ways to treat the hallmarks of Alzheimer's disease. Expert Opinion on Investigational Drugs. 16(8). 1183–1196. 18 indexed citations
16.
Nichols, Michael R. & Bruce H. Morimoto. (2000). Differential Inhibition of Multiple cAMP Phosphodiesterase Isozymes by Isoflavones and Tyrphostins. Molecular Pharmacology. 57(4). 738–745. 35 indexed citations
17.
Nichols, Michael R. & Bruce H. Morimoto. (1999). Tyrosine Kinase-Independent Inhibition of Cyclic-AMP Phosphodiesterase by Genistein and Tyrphostin 51. Archives of Biochemistry and Biophysics. 366(2). 224–230. 32 indexed citations
18.
Morimoto, Bruce H., Scott Lovell, & Bart Kahr. (1998). Ecstasy: 3,4-Methylenedioxymethamphetamine (MDMA). Acta Crystallographica Section C Crystal Structure Communications. 54(2). 229–231. 18 indexed citations
19.
Morimoto, Bruce H. & Daniel E. Koshland. (1991). Identification of cyclic AMP as the response regulator for neurosecretory potentiation: a memory model system.. Proceedings of the National Academy of Sciences. 88(23). 10835–10839. 19 indexed citations
20.
Morimoto, Bruce H. & D E Koshland. (1990). Induction and expression of long- and short-term neurosecretory potentiation in a neural cell line. Neuron. 5(6). 875–880. 129 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Laurent Lecanu Breakdown of academic impact, for papers by Marta Tajes Breakdown of academic impact, for papers by Xénia Latypova Breakdown of academic impact, for papers by Jan Říčný Breakdown of academic impact, for papers by Jian‐Sheng Kang Breakdown of academic impact, for papers by Joo‐Yong Lee Breakdown of academic impact, for papers by Shane E. Kruse Breakdown of academic impact, for papers by Zhongmin Xiang Breakdown of academic impact, for papers by Priyanka Narayan Breakdown of academic impact, for papers by Simona Magi
Rankless by CCL
2026